Beyond Oral Antidiabetics: Insulin Therapy Options and Combinations


You have to weigh the advantages of new and emerging products. For insulin, these include U300 insulin, U500 insulin, and insulin degludec; while these agents expand therapeutic options, they also complicate decisions for many pharmacists. Now, pharmacists must consider not only administration, storage, and counseling, but also access—because cost may be a barrier. During this session, experts will use patient cases to demonstrate the appropriate use of various insulin therapies and describe strategies that support patient access. 

Pharmacist Learning Objectives

At the completion of this knowledge-based activity, participants will be able to:

  1. Compare and contrast the characteristics of recently approved forms of insulin.
  2. Explain the potential roles of recently improved insulins in the management of type 1 and type 2 diabetes.
  3. Describe strategies to minimize insulin-induced hypoglycemia, including patient education tools.
  4. Select insulin administration aids based on patient characteristics.
  5. Describe skills that are effective for educating patients who are resistant to taking insulin.

Joint Providership

Supported by an independent educational grant from Novo Nordisk.



This activity is supported by an independent educational grant from Novo Nordisk, Inc.
Jennifer Trujillo,
University of Colorado Denver
Stuart Haines, PHARMD
Professor and Pharmacotherapy Specialist
University of Maryland School of Pharmacy
Learning Level: Level 3
Pathway: Meeting Highlights Video on Demand
Track: Health-System Pharmacy, Clinical Patient Care and Services
Session Time Slot(s): 
Sunday, March 26
1:00 PM - 3:00 PM
Moscone - Esplanade 307
ACPE Pharmacist: 0202-0000-17-058-L04-P
CEUs Pharmacist: .2
Activity Type: